Skip to main content

"Informed AI News" is an publications aggregation platform, ensuring you only gain the most valuable information, to eliminate information asymmetry and break through the limits of information cocoons. Find out more >>

FDA Approves New Alzheimer's Drug Donanemab

FDA Approves New Alzheimer's Drug Donanemab

FDA approves donanemab, a new Alzheimer's drug. Developed by Eli Lilly, it targets amyloid beta, a protein linked to nerve cell damage in Alzheimer's patients. The drug binds and removes this protein, slowing disease progression. The approval reflects the FDA's dedication to effective Alzheimer's treatments. Eli Lilly also seeks approval in Japan.

Amyloid beta: a protein that accumulates abnormally in Alzheimer's brains, believed to harm nerve cells.

Full article>>